ProCE Banner Activity

Assessing Risk and Individualizing Therapy in HR+/HER2- Early Breast Cancer

Slideset Download
Download these slides from an expert-led symposium reviewing the latest advances in targeted therapy for HR-positive/HER2-negative early-stage breast cancer.

Released: June 06, 2022

Expiration: June 05, 2023

No longer available for credit.

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Erica Mayer

Erica Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Program Director Disclosure

Program Director

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, SunPharma, and Taiho Oncology and funds for research support paid to her institution from ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, and Zymeworks.

Faculty Disclosure

Primary Author

Erica Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Erica L. Mayer, MD, MPH, has disclosed that he has received consulting fees from AstraZeneca, Gilead, Lilly, and Novartis.